Acrux Ltd (ASX:ACR) CEO and managing director Michael Kotsanis is in the Proactive studio following the 18th annual Bioshares Biotech Summit in Perth.
Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products.
Drawing on 25 years of experience, Acrux has marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products to bring affordable products to market. Acrux encourages collaboration and is positioned to discuss commercial partnering and product development opportunities.
_#ProactiveInvestors #Acrux #ASX #ACR #Biotech #Bioshares #Summit #BiosharesBiotechSummit
#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
view more